6.21 USD
-0.10
1.58%
At close Aug 1, 4:00 PM EDT
After hours
6.21
+0.00
0.00%
1 day
-1.58%
5 days
-8.81%
1 month
-12.54%
3 months
-12.04%
6 months
-45.86%
Year to date
-32.43%
1 year
-31.76%
5 years
-79.18%
10 years
-86.15%
 

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 766

0
Funds holding %
of 7,327 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,500% more call options, than puts

Call options by funds: $144K | Put options by funds: $9K

53% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 34

6% less funds holding

Funds holding: 135 [Q4 2024] → 127 (-8) [Q1 2025]

13.51% less ownership

Funds ownership: 84.33% [Q4 2024] → 70.82% (-13.51%) [Q1 2025]

23% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 22

27% less capital invested

Capital invested by funds: $184M [Q4 2024] → $134M (-$50.3M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$7
13%
upside
Avg. target
$11
77%
upside
High target
$14
125%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
B. Riley Securities
Anderson Schock
125%upside
$14
Buy
Initiated
16 Jun 2025
Needham
Mike Matson
93%upside
$12
Buy
Upgraded
22 May 2025
Stifel
Mathew Blackman
13%upside
$7
Hold
Maintained
8 May 2025

Financial journalist opinion

Neutral
Business Wire
2 weeks ago
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025.
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Neutral
Business Wire
1 month ago
Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy.
Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy
Positive
Zacks Investment Research
2 months ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Positive
Zacks Investment Research
2 months ago
3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties
Broker upgrades boost URBN, INGN and SWX, with earnings growth and strong Zacks Ranks signaling potential upside despite market volatility.
3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties
Positive
Benzinga
2 months ago
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough
Needham analyst Mike Matson upgraded Inogen, Inc INGN from Hold to Buy, with a price forecast of $12.
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough
Positive
Zacks Investment Research
2 months ago
What Makes Inogen (INGN) a New Buy Stock
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Inogen (INGN) a New Buy Stock
Negative
Zacks Investment Research
2 months ago
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)
Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)
Positive
Zacks Investment Research
2 months ago
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Neutral
Seeking Alpha
2 months ago
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Inogen, Inc. (NASDAQ:INGN ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Ryan Peterson - Investor Relations Kevin Smith - President and CEO Mike Bourque - CFO Conference Call Participants Colin Clark - Stifel Mike Matteson - Needham & Company Margaret Andrew - William Blair Operator Welcome to Inogen's First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen, Inc. (INGN) Q1 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™